Abstract
1. 1. Clinical activity, extrapyramidal side-effects were evaluated in 22 schizophrenic out patients diagnosed according to DSM III and treated with haioperidol decanoate (50-300 mg i.m. monthly dose) for 12 months. 2. 2. BPRS total scores did not show significant fluctuations showing a clinical stability of the patient population. 3. 3. Patients with a duration of illness > 10 yrs (Group 2) showed significant (p <0.01) higher EPSE total scores compared to those with a duration of illness <10 yrs (Group 1). 4. 4. A positive correlation was found between the administered dose and haloperidol plasma levels. 5. 5. Patients from Group 2 reached the steady-state more slowly and showed a lower total L/D ratio compared to those from Group 1. 6. 6. The pharmacokinetic approach seems desirable in order to adjust the dose and avoid schizophrenic relapses.
Original language | English |
---|---|
Pages (from-to) | 25-35 |
Number of pages | 11 |
Journal | Progress in Neuro-Psychopharmacology and Biological Psychiatry |
Volume | 14 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1990 |
Keywords
- C
- catatonic
- D
- DG
- diagnosis
- disorganized
- EPSE
- extrapyramidal side-effects rating scale
- haioperidol decanoate
- haloperidol
- haloperidol decanoate
- HL
- HL-D
- L/D
- level/dose ratio
- not performed
- NP
- P
- paranoid
- patient
- pharmacokinetics
- PL
- plasma levels
- PT
- schizophrenia
- SD
- standard deviation
- U
- undifferentiated
- years
- yrs
ASJC Scopus subject areas
- Biological Psychiatry
- Pharmacology